Additionally, several nicely founded adverse prognostic markers, which include U-CLL, ATM aberrations or NOTCH1/BIRC3 mutations, misplaced their destructive impact in clients treated with VO. The only issue that remained predictive of a shorter progression-no cost survival During this cohort of sufferers was TP53 aberrations.112 Last but not least,